Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Br J Haematol. 2015 Dec 18;172(5):794–806. doi: 10.1111/bjh.13862

Figure 7. Trans-resveratrol-treated platelets have a longer half-life and decreased thrombosis in vivo post-transfusion.

Figure 7

Blood was collected via retro-orbital bleeds from 30 C57Bl/6 mice, and platelet rich plasma (PRP) was generated via centrifugation. PRP was treated with vehicle (0.1% DMSO) or 10 μM trans-resveratrol and stored for 24 h at room temperature with gentle agitation. (A) Platelets were fluorescently labelled with CFSE and transfused into 8-week-old C57Bl/6 autologous recipients retro-orbitally. Blood was collected via retro-orbital bleed after 4, 24 or 48 h and the percentage of CFSE-positive platelets was determined by flow cytometry. n=12. Mean+/− SEM. Statistical significance was determined by Two-Way ANOVA with Bonferroni post-test. **p<0.01, ***p<0.001. (B) Fresh (C), control stored platelets (D), or resveratrol-treated stored platelets (10 μM; E) were fluorescently labelled with calcein-AM and transfused into 4-week-old C57Bl/6 autologous recipients retro-orbitally. 10% ferric chloride was applied to a mesenteric arteriole to initiate thrombosis. Blood flow was visualized by intravital microscopy; dotted lines indicate vessel wall location. Images from 650 s are shown for one representative animal (C–E) and the time to full vessel occlusion was measured (B). Statistical significance was determined by One-Way ANOVA with Tukey post-test. *p<0.05, ***p<0.001